Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ariel Sindel

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Current Treatment Options in Oncology|December 7, 2019
Marginal Zone Lymphoma: State-of-the-Art TreatmentAriel Sindel, Taha Al-Juhaishi, Victor Yazbeck
Expert Opinion on Pharmacotherapy|February 19, 2020
Perspectives on chemotherapy for the management of double-hit lymphomaTaha Al-Juhaishi, John Mckay, Ariel Sindel, et al.
Expert Opinion on Pharmacotherapy|August 17, 2024
New and developing first line pharmacotherapies for treating non-Hodgkin lymphomaBruce Hough, Olga Lytvynova, Ariel Sindel, et al.
The British Journal of Dermatology|February 11, 2026
Durable disease control of adult-onset xanthogranuloma with time-limited MEK inhibition: a case reportHyun Lee, Ellie McCabe, Thuy Ho, et al.
CJC Open|March 7, 2023
Multiple Immunotherapy-Related Cardiovascular SequelaeSherin M Menachery, David Chuquin, Ariel Sindel, et al.
European Journal of Haematology|May 30, 2019
Hematopoietic stem cell mobilization following PD-1 blockade: Cytokine release syndrome after transplantation managed with ascorbic acidAriel Sindel, Trevor Taylor, Alden Chesney, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Current Treatment Options in Oncology|December 7, 2019
Marginal Zone Lymphoma: State-of-the-Art TreatmentAriel Sindel, Taha Al-Juhaishi, Victor Yazbeck
Expert Opinion on Pharmacotherapy|February 19, 2020
Perspectives on chemotherapy for the management of double-hit lymphomaTaha Al-Juhaishi, John Mckay, Ariel Sindel, et al.
Expert Opinion on Pharmacotherapy|August 17, 2024
New and developing first line pharmacotherapies for treating non-Hodgkin lymphomaBruce Hough, Olga Lytvynova, Ariel Sindel, et al.
The British Journal of Dermatology|February 11, 2026
Durable disease control of adult-onset xanthogranuloma with time-limited MEK inhibition: a case reportHyun Lee, Ellie McCabe, Thuy Ho, et al.
CJC Open|March 7, 2023
Multiple Immunotherapy-Related Cardiovascular SequelaeSherin M Menachery, David Chuquin, Ariel Sindel, et al.
European Journal of Haematology|May 30, 2019
Hematopoietic stem cell mobilization following PD-1 blockade: Cytokine release syndrome after transplantation managed with ascorbic acidAriel Sindel, Trevor Taylor, Alden Chesney, et al.
Pageof 1